CARLEY BUDDENBAUM: Open Payments
NPI 1982174074 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,261 in 251 payments from 22 companies in 2025. Trend: 2023 $3,410 · 2024 $5,117 · 2025 $5,261
Food & beverage: $5,200Education: $61
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 49 | $998 |
| Janssen Biotech, Inc. | 23 | $612 |
| PFIZER INC. | 16 | $389 |
| GENZYME CORPORATION | 17 | $385 |
| Galderma Laboratories, L.P. | 22 | $384 |
| Novartis Pharmaceuticals Corporation | 15 | $381 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 13 | $287 |
| Amgen Inc. | 15 | $275 |
| Regeneron Healthcare Solutions, Inc. | 14 | $244 |
| Lilly USA, LLC | 11 | $196 |
Products named: DUPIXENT, TREMFYA, SKYRIZI, RINVOQ, NEMLUVIO, CIBINQO, COSENTYX, TALTZ.
Industry payments across TX — which companies pay providers there.
